Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

A doctor at Monday’s event said some of the reasons for Iowa’s increased cancer rate include HPV, alcohol use, and the state’s higher obesity rate.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

There is a positive association between exposure to at least 1 head/neck CT scan and the risk for pediatric brain tumors.